Pulmonary Disease, Chronic ObstructivePhase 3NCT01533922

Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients

A Phase 3 study testing Tiotropium, Olodaterol and tiotropium + olodaterol in people with Pulmonary Disease, Chronic Obstructive, run by Boehringer Ingelheim at 44 sites in 10 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

The primary objective of this trial is to investigate the effect of 6 weeks treatment with tiotropium + olodaterol fixed dose combination inhalation solution on lung hyperinflation and exercise tolerance in patients with COPD Read more about this study

Who is it for?: Ages 40 to 75 years
Conditions the study is for: Pulmonary Disease, Chronic Obstructive
What is being tested?: Tiotropium, Olodaterol and tiotropium + olodaterol
Type of treatment: Medical device
Could I receive a placebo?: Yes, some participants may receive a placebo
How many people: 295 participants
Where: 44 sitesin 10 countries
Study dates: Mar 2012to Nov 2013
Phase: Phase 3
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 40 to 75 years
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

All patients must sign an informed consent consistent with ICH-GCP guidelines prior to participation in the trial, which includes medication washout and restrictions.
All patients must have a diagnosis of chronic obstructive pulmonary disease and must meet the following spirometric criteria:
Patients must have relatively stable airway obstruction with a post-bronchodilator FEV1 <80% of predicted normal and a post-bronchodilator FEV1/FVC <70% at Visit 1.
Male or female patients, between 40 and 75 years of age (inclusive) on day of signing informed consent.
Patients must be current or ex-smokers with a smoking history of more than 10 pack years.

Who cannot join

Patients with a significant disease other than COPD; a significant disease is defined as a disease which, in the opinion of the investigator, may (i) put the patient at risk because of participation in the study, (ii) influence the results of the study, or (iii) cause concern regarding the patient's ability to participate in the study
Patients with clinically relevant abnormal baseline haematology, blood chemistry, or urinalysis; all patients with an SGOT >x2 ULN, SGPT >x2 ULN, bilirubin >x2 ULN or creatinine >x2 ULN will be excluded regardless of clinical condition
Patients with a history of asthma. For patients with allergic rhinitis or atopy, source documentation is required to verify that the patient does not have asthma.
Patients with any of the following conditions:
A diagnosis of thyrotoxicosis (due to the known class side effect profile of ß2-agonists)
A diagnosis of paroxysmal tachycardia (>100 beats per minute) (due to the known class side effect profile of ß2-agonists)

Show all 26Show fewer

A history of myocardial infarction within 1 year of screening visit (Visit 1)
Unstable or life-threatening cardiac arrhythmia
Hospitalized for heart failure within the past year
Known active tuberculosis
A malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years (patients with treated basal cell carcinoma are allowed)
A history of life-threatening pulmonary obstruction
A history of cystic fibrosis
Clinically evident bronchiectasis
A history of significant alcohol or drug abuse
Any contraindications for exercise testing.
Patients who have undergone thoracotomy with pulmonary resection (patients with a history of thoracotomy for other reasons should be evaluated as per exclusion criterion No. 1)
Patients being treated with any oral ß-adrenergics
Patients being treated with oral corticosteroid medication at unstable doses
Patients who regularly use daytime oxygen therapy for more than one hour per day and in the investigator's opinion will be unable to abstain from the use of oxygen therapy during clinic visits
Patients who have completed a pulmonary rehabilitation program in the six weeks prior to the screening visit or patients who are currently in a pulmonary rehabilitation program
Patients who have a limitation of exercise performance as a result of factors other than fatigue or exertional dyspnoea, such as arthritis in the leg, angina pectoris or claudication or morbid obesity.
Patients who have taken an investigational drug within one month or six half lives (whichever is greater) prior to screening visit
Patients with known hypersensitivity to ß-adrenergics drugs, anticholinergic drugs, BAC, EDTA or any other component of the Respimat® inhalation solution delivery system
Pregnant or nursing women
Women of childbearing potential not using highly effective methods of birth control.

Trial locations and contacts

44 sites in 10 countries.

Country

City, postcode or hospital

44 sites in 10 countries

Italy9 sites

1237.13.39302 Boehringer Ingelheim Investigational Site
Genova
1237.13.39304 Boehringer Ingelheim Investigational Site
Parma
1237.13.39303 Boehringer Ingelheim Investigational Site
Pavia
1237.13.39305 Boehringer Ingelheim Investigational Site
Pavullo Nel Frignano (mo)
1237.13.39301 Boehringer Ingelheim Investigational Site
Pisa
1237.13.39312 Boehringer Ingelheim Investigational Site
Pisa
1237.13.39310 Boehringer Ingelheim Investigational Site
Roma
1237.13.39308 Boehringer Ingelheim Investigational Site
Sesto S. Giovanni (mi)
1237.13.39306 Boehringer Ingelheim Investigational Site
Trieste

Other trials in Italy

United States8 sites

1237.13.01305 Boehringer Ingelheim Investigational Site
Easley, South Carolina
1237.13.01301 Boehringer Ingelheim Investigational Site
Greenville, South Carolina
1237.13.01308 Boehringer Ingelheim Investigational Site
Hartford, Connecticut
1237.13.01304 Boehringer Ingelheim Investigational Site
Livonia, Michigan
1237.13.01307 Boehringer Ingelheim Investigational Site
Pittsburgh, Pennsylvania
1237.13.01306 Boehringer Ingelheim Investigational Site
Richmond, Virginia
1237.13.01303 Boehringer Ingelheim Investigational Site
Spartanburg, South Carolina
1237.13.01302 Boehringer Ingelheim Investigational Site
Torrance, California

Other trials in United States

Germany6 sites

1237.13.49302 Boehringer Ingelheim Investigational Site
Berlin
1237.13.49307 Boehringer Ingelheim Investigational Site
Dortmund
1237.13.49304 Boehringer Ingelheim Investigational Site
Frankfurt
1237.13.49301 Boehringer Ingelheim Investigational Site
Halle
1237.13.49303 Boehringer Ingelheim Investigational Site
Hanover
1237.13.49305 Boehringer Ingelheim Investigational Site
Lübeck

Other trials in Germany

Australia5 sites

1237.13.61306 Boehringer Ingelheim Investigational Site
Concord, New South Wales
1237.13.61301 Boehringer Ingelheim Investigational Site
Daw Park, South Australia
1237.13.61304 Boehringer Ingelheim Investigational Site
Footscray, Victoria
1237.13.61302 Boehringer Ingelheim Investigational Site
Prahran, Victoria
1237.13.61305 Boehringer Ingelheim Investigational Site
Toorak Gardens, South Australia

Other trials in Australia

Belgium5 sites

1237.13.32302 Boehringer Ingelheim Investigational Site
Brussels
1237.13.32303 Boehringer Ingelheim Investigational Site
Edegem
1237.13.32305 Boehringer Ingelheim Investigational Site
Jambes
1237.13.32304 Boehringer Ingelheim Investigational Site
Lanaken
1237.13.32301 Boehringer Ingelheim Investigational Site
Leuven

Other trials in Belgium

Canada3 sites

1237.13.11302 Boehringer Ingelheim Investigational Site
Hamilton, Ontario
1237.13.11303 Boehringer Ingelheim Investigational Site
Kingston, Ontario
1237.13.11304 Boehringer Ingelheim Investigational Site
Saskatoon, Saskatchewan

Other trials in Canada

Argentina2 sites

1237.13.54301 Boehringer Ingelheim Investigational Site
Capital Federal
1237.13.54302 Boehringer Ingelheim Investigational Site
Mar del Plata

Other trials in Argentina

Austria2 sites

1237.13.43303 Boehringer Ingelheim Investigational Site
Linz
1237.13.43301 Boehringer Ingelheim Investigational Site
Thalheim bei Wels

Other trials in Austria

Chile2 sites

1237.13.56301 Boehringer Ingelheim Investigational Site
Chile
1237.13.56302 Boehringer Ingelheim Investigational Site
Santiago

Other trials in Chile

New Zealand2 sites

1237.13.64302 Boehringer Ingelheim Investigational Site
Christchurch
1237.13.64301 Boehringer Ingelheim Investigational Site
Greenlane East Auckland NZ

Other trials in New Zealand

About this study

Official title: A Randomised, Double-blind, 5 Treatment Arms, 4-period, Incomplete Cross-over Study to Determine the Effect of 6 Weeks Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (FDC) (2.5 / 5 µg; and 5 / 5 µg) (Delivered by the Respimat® Inhaler) Compared With Tiotropium (5 µg), Olodaterol (5 µg ) and Placebo (Delivered by the Respimat® Inhaler) on Lung Hyperinflation and Exercise Endurance Time During Constant Work Rate Cycle Ergometry in Patients With Chronic Obstructive Pulmonary Disease (COPD) [MORACTO TM 1]

Conditions: Pulmonary Disease, Chronic Obstructive
Being tested: Placebo, Tiotropium, Olodaterol, tiotropium + olodaterol, Respimat
Medical subject headings: Pulmonary Disease, Chronic Obstructive

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

PlaceboDrug
placebo matching tiotropium + olodaterol FDC
TiotropiumDrug
Tiotropium 5 mcg once daily
OlodaterolDrug
Olodaterol 5 mcg once daily
tiotropium + olodaterolDrug
tiotropium + olodaterol 5 mcg once daily
Tiotropium + OlodaterolDrug
Tiotropium 2.5 mcg + Olodaterol 5 mcg once daily
RespimatDevice
Respimat inhaler

Study groups in NCT01533922
Study group	Role	What they receive
Tiotropium + olodaterol High dose QD	Experimental	patient will receive tiotropium 5 mcg + olodaterol 5 mcg in a fixed dose combination once daily Receives: Drug: tiotropium + olodaterol; Device: Respimat
Tiotropium + olodaterol Low dose QD	Experimental	patient will receive tiotropium 2.5 mcg + olodaterol 5 mcg in a fixed dose combination once daily Receives: Drug: Tiotropium + Olodaterol; Device: Respimat
Tiotropium 5 mcg QD	Active comparator	patient will receive tiotropium 5 mcg once daily Receives: Drug: Tiotropium; Device: Respimat
Olodaterol 5 mcg QD	Active comparator	patient will receive olodaterol 5 mcg once daily Receives: Drug: Olodaterol; Device: Respimat
Placebo QD	Placebo comparator	Not described Receives: Drug: Placebo; Device: Respimat

What is being measured

The primary outcome is the main question the study is designed to answer.

Inspiratory Capacity at Rest Before Constant Work Rate Cycle Ergometry to Symptom Limitation at 75% Wcap
Inspiratory capacity (IC) at rest before constant work rate cycle ergometry to symptom limitation at 75% maximal work capacity (Wcap).
Wcap was defined as the maximum work rate achieved for at least 30 seconds during the incremental cycle ergometry performed at Visit 1.
The presented means are adjusted means from the MMRM (Mixed Effects Model Repeated Measures) model.
Measured: 6 weeks
Endurance Time During Constant Work Rate Cycle Ergometry to Symptom Limitation at 75% Wcap
Endurance time during constant work rate cycle ergometry (CWRCE) to symptom limitation at 75% work capacity (Wcap).
Wcap was defined as the maximum work rate achieved for at least 30 seconds during the incremental cycle ergometry performed at Visit 1.
The presented means are adjusted mean from the MMRM model.
Measured: 6 weeks

Secondary outcomes (2)

Slope of the Intensity of Breathing Discomfort During Constant Work Rate Cycle Ergometry to Symptom Limitation at 75% Work Capacity
Slope of the intensity of breathing discomfort during Constant Work Rate Cycle Ergometry (CWRCE) to symptom limitation at 75% Work capacity (Wcap). The intensity of breathing discomfort was rated using the modified Borg scale with ratings from 0 (nothing at all) to 10 (maximal).
Slope of breathing discomfort is defined as: (intensity of breathing discomfort at the end of exercise minus intensity of breathing discomfort at rest) / endurance time.
A decrease in slope indicates improvement.
The presented means are adjusted means from MMRM model.
Measured: 6 weeks
Forced Expiratory Volume in 1 Second (One Hour Post-dose)
Forced Expiratory Volume in 1 Second (FEV1) (one hour post-dose)
The presented means are adjusted means from MMRM model.
Measured: 6 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

Mar 2012Nov 2013

First posted16 Feb 2012 (estimated)
Study startMar 2012
Primary completionNov 2013
Study completionNov 2013

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Publications (1)Papers the sponsor has linked to this study.
Other trials for Pulmonary Disease, Chronic ObstructiveStudies of the same condition, open and under way.
More trials run by Boehringer IngelheimThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 3
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Crossover
Masking: Double blind
Enrolment: 295 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT01533922
Sponsor's protocol ID: 1237.13
Other IDs: 2011-004659-37
Status last verified: Aug 2015
First submitted: 13 Feb 2012
Last updated: 15 Sep 2015
Results posted: Yes, on ClinicalTrials.gov

Publications

O'Donnell DE, Casaburi R, Frith P, Kirsten A, De Sousa D, Hamilton A, Xue W, Maltais F. Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD. Eur Respir J. 2017 Apr 19;49(4):1601348. doi: 10.1183/13993003.01348-2016. Print 2017 Apr.
PubMed 28424359

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Active, not recruiting
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
COPD, Smoking
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Not yet recruiting
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly
Not yet recruitingPhase 2
Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease
Chronic Graft Versus Host Disease

All Pulmonary Disease, Chronic Obstructive trials

Study at a glance

From the registry record, last updated by the sponsor on 15 Sep 2015. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Randomised, Double-blind, 5 Treatment Arms, 4-period, Incomplete Cross-over Study to Determine the Effect of 6 Weeks Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (FDC) (2.5 / 5 µg; and 5 / 5 µg) (Delivered by the Respimat® Inhaler) Compared With Tiotropium (5 µg), Olodaterol (5 µg ) and Placebo (Delivered by the Respimat® Inhaler) on Lung Hyperinflation and Exercise Endurance Time During Constant Work Rate Cycle Ergometry in Patients With Chronic Obstructive Pulmonary Disease (COPD) [MORACTO TM 1]
ClinicalTrials.gov ID: NCT01533922
Acronym / sponsor ID: 1237.13
Conditions: Pulmonary Disease, Chronic Obstructive
Phase: Phase 3
Study type: Interventional
Recruitment status: Completed
Enrolment: 295 participants (actual)
Lead sponsor: Boehringer IngelheimIndustry (pharma, biotech, devices)
Study start: Mar 2012
Primary completion: Nov 2013 (actual)
Study completion: Nov 2013 (actual)
First posted: 16 Feb 2012 (estimated)
Results: Posted 15 Sep 2015

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Crossover
Masking: Double blind
Number of arms: 5

Arm	Type	Receives
Tiotropium + olodaterol High dose QD	Experimental	Drug: tiotropium + olodaterol, Device: Respimatpatient will receive tiotropium 5 mcg + olodaterol 5 mcg in a fixed dose combination once daily
Tiotropium + olodaterol Low dose QD	Experimental	Drug: Tiotropium + Olodaterol, Device: Respimatpatient will receive tiotropium 2.5 mcg + olodaterol 5 mcg in a fixed dose combination once daily
Tiotropium 5 mcg QD	Active comparator	Drug: Tiotropium, Device: Respimatpatient will receive tiotropium 5 mcg once daily
Olodaterol 5 mcg QD	Active comparator	Drug: Olodaterol, Device: Respimatpatient will receive olodaterol 5 mcg once daily
Placebo QD	Placebo comparator	Drug: Placebo, Device: Respimat

Who may qualify

Ages: 40 to 75 years
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (5 listed)

All patients must sign an informed consent consistent with ICH-GCP guidelines prior to participation in the trial, which includes medication washout and restrictions.
All patients must have a diagnosis of chronic obstructive pulmonary disease and must meet the following spirometric criteria:
Patients must have relatively stable airway obstruction with a post-bronchodilator FEV1 <80% of predicted normal and a post-bronchodilator FEV1/FVC <70% at Visit 1.
Male or female patients, between 40 and 75 years of age (inclusive) on day of signing informed consent.
Patients must be current or ex-smokers with a smoking history of more than 10 pack years.

Key exclusion criteria (26 listed)

Patients with a significant disease other than COPD; a significant disease is defined as a disease which, in the opinion of the investigator, may (i) put the patient at risk because of participation in the study, (ii) influence the results of the study, or (iii) cause concern regarding the patient's ability to participate in the study
Patients with clinically relevant abnormal baseline haematology, blood chemistry, or urinalysis; all patients with an SGOT >x2 ULN, SGPT >x2 ULN, bilirubin >x2 ULN or creatinine >x2 ULN will be excluded regardless of clinical condition
Patients with a history of asthma. For patients with allergic rhinitis or atopy, source documentation is required to verify that the patient does not have asthma.
A diagnosis of thyrotoxicosis (due to the known class side effect profile of ß2-agonists)
A diagnosis of paroxysmal tachycardia (>100 beats per minute) (due to the known class side effect profile of ß2-agonists)

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Placeboplacebo matching tiotropium + olodaterol FDC	Drug	Placebo QD
TiotropiumTiotropium 5 mcg once daily	Drug	Tiotropium 5 mcg QD
OlodaterolOlodaterol 5 mcg once daily	Drug	Olodaterol 5 mcg QD
tiotropium + olodateroltiotropium + olodaterol 5 mcg once daily	Drug	Tiotropium + olodaterol High dose QD
Tiotropium + OlodaterolTiotropium 2.5 mcg + Olodaterol 5 mcg once daily	Drug	Tiotropium + olodaterol Low dose QD
RespimatRespimat inhaler	Device	Olodaterol 5 mcg QD, Placebo QD, Tiotropium + olodaterol High dose QD, Tiotropium + olodaterol Low dose QD, Tiotropium 5 mcg QD

Primary outcome

Inspiratory Capacity at Rest Before Constant Work Rate Cycle Ergometry to Symptom Limitation at 75% Wcap
Time frame: 6 weeks
Inspiratory capacity (IC) at rest before constant work rate cycle ergometry to symptom limitation at 75% maximal work capacity (Wcap). Wcap was defined as the maximum work rate achieved for at least 30 seconds during the incremental cycle ergometry performed at Visit 1. The presented means are adjusted means from the MMRM (Mixed Effects Model Repeated Measures) model.
Endurance Time During Constant Work Rate Cycle Ergometry to Symptom Limitation at 75% Wcap
Time frame: 6 weeks
Endurance time during constant work rate cycle ergometry (CWRCE) to symptom limitation at 75% work capacity (Wcap). Wcap was defined as the maximum work rate achieved for at least 30 seconds during the incremental cycle ergometry performed at Visit 1. The presented means are adjusted mean from the MMRM model.

2 secondary outcomes

Slope of the Intensity of Breathing Discomfort During Constant Work Rate Cycle Ergometry to Symptom Limitation at 75% Work Capacity
Time frame: 6 weeks
Forced Expiratory Volume in 1 Second (One Hour Post-dose)
Time frame: 6 weeks

Results and safety

Results posted to the registry on 15 Sep 2015, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Tio+Olo 2.5/5 / Tio+Olo 5/5 / Tio / Olo	59	49
Tio+Olo 5/5 / Tio / Olo / Placebo	59	47
Tio / Olo / Placebo / Tio+Olo 2.5/5	60	50
Olo / Placebo / Tio+Olo 2.5/5 / Tio+Olo 5/5	58	53
Placebo / Tio+Olo 2.5/5 / Tio+Olo 5/5 / Tio	59	53

Primary outcome: Inspiratory Capacity at Rest Before Constant Work Rate Cycle Ergometry to Symptom Limitation at 75% Wcap

Time frame: 6 weeks. Mean (Standard Error). Unit: Litres

Measure	Placebo n = 211	Olodaterol 5 µg n = 214	Tiotropium 5 µg n = 213	Tiotropium + Olodaterol 2.5/5 n = 214	Tiotropium + Olodaterol 5/5 n = 219
Value	2.440 (0.027)	2.566 (0.027)	2.571 (0.027)	2.658 (0.027)	2.685 (0.027)

Placebo vs Tiotropium + Olodaterol 5/5: Mean Difference (Final Values): 0.244 (95% CI 0.191 to 0.298), p <0.0001, Mixed Models Analysis
Olodaterol 5 µg vs Tiotropium + Olodaterol 5/5: Mean Difference (Final Values): 0.119 (95% CI 0.065 to 0.172), p <0.0001, Mixed Models Analysis
Tiotropium 5 µg vs Tiotropium + Olodaterol 5/5: Mean Difference (Final Values): 0.114 (95% CI 0.061 to 0.167), p <0.0001, Mixed Models Analysis

Population analysed: Full Analysis Set (FAS) : This patient set included all patients in the TS who had the study baseline and at least 1 evaluable post-dose measurement for 1 of the primary endpoints. Assignment to the FAS was done after implementation of any data handling rules,which set measurements to missing.

Primary outcome: Endurance Time During Constant Work Rate Cycle Ergometry to Symptom Limitation at 75% Wcap

Time frame: 6 weeks. Geometric mean (Standard Error). Unit: seconds

Measure	Placebo n = 209	Olodaterol 5 µg n = 208	Tiotropium 5 µg n = 209	Tiotropium + Olodaterol 2.5/5 n = 212	Tiotropium + Olodaterol 5/5 n = 212
Value	375.45 (12.037)	453.38 (14.552)	457.16 (14.652)	474.80 (15.145)	454.08 (14.474)

Placebo vs Tiotropium + Olodaterol 5/5: Ratio: 1.209 (95% CI 1.132 to 1.292), p <0.0001, Mixed Models Analysis
Olodaterol 5 µg vs Tiotropium + Olodaterol 5/5: Ratio: 1.002 (95% CI 0.937 to 1.070), p = 0.9633, Mixed Models Analysis
Tiotropium 5 µg vs Tiotropium + Olodaterol 5/5: Ratio: 0.993 (95% CI 0.930 to 1.061), p = 0.8415, Mixed Models Analysis

Population analysed: FAS

2 secondary outcomes are reported in the full results.

Adverse events

Time frame: From drug administration until 21 days after the last administration, up to 120 days. Other adverse events reported at 5% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Placebo	4 of 222 (1.8%)	26 of 222 (11.7%)	Not reported
Olodaterol 5 µg	3 of 217 (1.4%)	17 of 217 (7.8%)	Not reported
Tiotropium 5 µg	8 of 226 (3.5%)	20 of 226 (8.8%)	Not reported
Tiotropium + Olodaterol 2.5/5	5 of 222 (2.3%)	13 of 222 (5.9%)	Not reported
Tiotropium + Olodaterol 5/5	6 of 226 (2.7%)	19 of 226 (8.4%)	Not reported

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 15 Sep 2015.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Derived from this study: PubMed 28424359O'Donnell DE, Casaburi R, Frith P, Kirsten A, De Sousa D, Hamilton A, Xue W, Maltais F. Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD. Eur Respir J. 2017 Apr 19;49(4):1601348. doi: 10.1183/13993003.01348-2016. Print 2017 Apr.
Related InfoLink provided by the sponsor.

Related trials for Pulmonary Disease, Chronic Obstructive

Active, not recruiting
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
COPD, Smoking
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Not yet recruiting
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly
Not yet recruitingPhase 2
Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease
Chronic Graft Versus Host Disease

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Boehringer Ingelheim study chair

Boehringer Ingelheim

44 sites in 10 countries: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Tiotropium, Olodaterol and tiotropium + olodaterol in people with Pulmonary Disease, Chronic Obstructive, run by Boehringer Ingelheim at 44 sites in 10 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 26 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Sep 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 44 sites in Italy, United States, Germany, Australia, Belgium and 5 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 15 Sep 2015). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Inspiratory Capacity at Rest Before Constant Work Rate Cycle Ergometry to Symptom Limitation at 75% Wcap (time frame: 6 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01533922, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Sep 2015.